COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01846390
Recruitment Status : Completed
First Posted : May 3, 2013
Last Update Posted : November 27, 2019
Information provided by (Responsible Party):
Canadian Cancer Trials Group

Brief Summary:
This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type and severity of side effects will result from the combination of these treatments. This research is also being done because it is not clear if the addition of the new drug romidepsin to treatment with GDP can offer better results and longer survival.

Condition or disease Intervention/treatment Phase
Peripheral T-Cell Lymphoma Diffuse Large B-Cell Lymphoma Drug: Gemcitabine Drug: Dexamethasone Drug: Cisplatin Drug: Romidepsin Phase 1

Detailed Description:
The purpose of this study is to find the highest dose of romidepsin that can safely be given in combination with gemcitabine, dexamethasone, and cisplatin (GDP) without causing very severe side effects that are not tolerable. This is done by starting at a dose lower than the one that does not cause side effects in animals. Patients are given romidepsin and GDP and watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more patients are asked to join the study and are given a higher dose of romidepsin (with GDP). Patients joining the study later on will get higher doses of romidepsin (with GDP) than patients who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Actual Study Start Date : April 30, 2013
Actual Primary Completion Date : July 6, 2016
Actual Study Completion Date : September 19, 2018

Arm Intervention/treatment
Experimental: romidepsin, gemcitabine, dexamethasone and cisplatin
A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
Drug: Gemcitabine
Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.

Drug: Dexamethasone
40 mg D1 - D4

Drug: Cisplatin
75 mg/m2 D1

Drug: Romidepsin
Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.

Primary Outcome Measures :
  1. Maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin. [ Time Frame: 48 months ]

    Combination of GDP with romidepsin at the maximum tolerated doses of these agents will identify the combination regimen for comparison in the subsequent randomized phase II trial; if romidepsin appears to improve the activity of GDP, then this will move forward to a formal phase III comparison to CHOP.

    Primary end points are toxicity, the maximum administered dose and the recommended phase II dose.

Secondary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: 48 months ]
    Adverse events by grade, dose level and total incidence; vital signs will be summarized and DLTs reported separately

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically confirmed PTCL. Biopsy proof of disease at initial diagnosis is mandatory. A biopsy at relapse is preferred but not mandatory.
  • Patients must have received one or two previous regimens of therapy for their disease (salvage chemotherapy plus autologous stem cell transplantation is considered to be one regimen).
  • Clinically and / or radiologically measurable disease (1 site bidimensionally measurable). Measurements / evaluations must be done within 28 days prior to registration.
  • Age 18 to 75 years.
  • ECOG performance status 0, 1 or 2.
  • Life expectancy of ≥ 90 days (3 months).
  • Laboratory Requirements: (must be done within 7 days of registration)


  • Granulocytes (AGC) ≥ 1.0 x 10^9/L
  • Platelets ≥ 75 x 10^9/L (≥ 50 if bone marrow involvement by lymphoma)


  • AST and ALT ≤ 2.5x ULN (≤ 5x ULN if hepatic involvement of disease)
  • Serum total bilirubin ≤ 1.5x ULN (≤ 3x ULN if hepatic involvement of disease, or ≤5x ULN if Gilberts Disease)
  • Serum Potassium ≥ 3.8 mmol/L*
  • Serum Magnesium ≥ 0.85 mmol/L* * NB: Patients with potassium and magnesium levels below these values are eligible if supplementation has corrected these deficits. This supplementation should continue throughout the course of the study.

    • Calculated creatinine clearance (Cockcroft-Gault formula) of ≥ 50 mL /min.
    • Women must be post-menopausal, surgically sterile or use reliable forms of contraception while on study and for 90 days after discontinuing therapy. Women of childbearing potential must have a pregnancy test taken and proven negative within 7 days prior to registration and must not be lactating.
    • Patient consent must be obtained according to local Institutional and/or University Human Experimentation Committee requirements.
    • Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
    • In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working days of patient registration.

Exclusion Criteria:

  • Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer and superficial bladder cancer, curatively treated in-situ cancer of the cervix or breast or localized excised prostate cancer, or other solid tumours curatively treated with no evidence of disease for ≥ 3 years.
  • Central nervous system involvement, meningeal or parenchymal. Patients with CNS disease at initial presentation and who are in a CNS CR at the time of relapse are eligible. MRI scanning and / or lumbar puncture should be performed if there is clinical suspicion of active CNS disease.
  • HIV, active hepatitis B or current hepatitis C infection. (Hepatitis B core antibody positive, surface antigen negative patients allowed if concurrent anti-viral prophylaxis is administered. Patients with a past history of hepatitis C who have eradicated the virus are eligible.)
  • Any serious active disease or co-morbid medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating (according to investigator's decision).
  • Patients with serious cardiac illness or condition including, but not limited to:

    • history of documented congestive heart failure (CHF)
    • systolic dysfunction (LVEF < 45% by MUGA or ECHO)
    • high risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled)
    • unstable angina pectoris requiring anti-anginal medication
    • clinically significant valvular heart disease
    • evidence of transmural infarction on ECG
    • New York Heart Association (NYHA) Class III or IV functional status
    • patients with congenital long QT syndrome, history of significant cardiovascular disease and/or taking drugs leading to significant QT prolongation
    • patients with QTc > 480 msec are not eligible
  • Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study.
  • Patients with active or uncontrolled infections, or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol are not eligible.
  • Patients are not eligible if they have a known hypersensitivity to the study drugs or their components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01846390

Layout table for location information
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, New Brunswick
Regional Health Authority B, Zone 2
Saint John, New Brunswick, Canada, E2L 4L2
Canada, Nova Scotia
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Canadian Cancer Trials Group
Layout table for investigator information
Study Chair: Anthony J Reiman Atlantic Health Sciences Corp - Saint John Regional Hospital, Saint John NB Canada
Study Chair: Kerry J Savage BCCA Vancouver Cancer Centre, Vancouver BC Canada

Publications of Results:
Layout table for additonal information
Responsible Party: Canadian Cancer Trials Group Identifier: NCT01846390    
Other Study ID Numbers: LY15
First Posted: May 3, 2013    Key Record Dates
Last Update Posted: November 27, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Dexamethasone acetate
BB 1101
Antineoplastic Agents
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Protease Inhibitors